Market Intelligence, Clinical Progress, and High-Purity Reagents for Parkinson's, Cognitive Disorders, and Neuropsychiatric Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DRD1/D1R drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DRD1 Recombinant Protein (N-terminal ECD / Full-Length options) — High purity (>95%), Endotoxin <1EU/ug, Sequence Verified, HEK293 expressed (Native Glycosylation). | View DRD1 Products |
| Gene Delivery (Lentivirus) | DRD1/D1R Lentivirus Premade Particles — Full-length ORF for stable cell line construction. High titer (>10^8 TU/ml), Sequence Verified. Preserves native membrane conformation. | View DRD1 Products |
| ORF Clone | DRD1 Promise-ORF — Codon-optimized for mammalian expression. Ready for calcium flux and cAMP assays. Sequence Verified. | View DRD1 Products |
| Benchmark Ab | Anti-DRD1 Recombinant Antibody — Recombinant positive control for assay calibration. High purity (>95%), Endotoxin <1EU/ug. | View DRD1 Products |
| Validator | DRD1 siRNA Set — For knockdown verification and specificity controls in signaling assays. 3 unique sequences. | View DRD1 Products |
| Related Target A | DRD5 (Dopamine Receptor D5) — D1-like family member, co-expressed in striatum, critical for selectivity profiling. | View DRD5 Products |
| Related Target B | ADORA2A (Adenosine A2A Receptor) — Forms heterodimers with DRD1 in striatal neurons, modulates Gs coupling efficiency. | View ADORA2A Products |
| Related Target C | DRD2 (Dopamine Receptor D2) — Antagonistic signaling pathway (Gi vs Gs), essential for counter-screening. | View DRD2 Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity (7-TM preservation) | Full-Length ORF Delivered via Lentivirus. Native membrane insertion guaranteed. HEK293 expression system maintains post-translational modifications. |
| D1 vs D5 Subfamily Off-target Screening | Comprehensive DRD1/DRD5 lentivirus/ORF panels strictly verified by sequencing for accurate subtype selectivity. |
| Cross-species Evaluation (Cyno/Mouse/Rat) | Ortholog ORF Clones Available (Human/Mouse/Cyno) with sequence identity verification for translational pharmacology. |
| Gs-coupled cAMP Assay Standardization | High-titer Lentivirus enables stable CHO-K1 or HEK293-DRD1 cell line construction for consistent EC50 determination. |
| Heterodimerization Studies (A2AR-DRD1) | Dual-transduction protocols supported. Co-expression validated by FRET/Flow cytometry. |
| Lack of Reliable Controls | Recombinant Benchmark Antibodies available with guaranteed theoretical MW and high purity. |
| Assay False Positives | Sequence-verified siRNA included for precise background knockdown and specificity validation. |
Live DRD1/D1R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DRD1/D1R therapeutics is intensifying, with major players shifting focus from traditional non-selective catecholamines to highly selective non-catecholamine agonists, biased ligands, and positive allosteric modulators (PAMs). First-generation D1 agonists faced tolerability and desensitization challenges in the clinic; the next wave targets biased signaling (G-protein over β-arrestin) to maximize efficacy in Parkinson's disease (PD) while minimizing receptor desensitization and dyskinesia. Concurrently, interest in DRD1–ADORA2A heterodimer biology is opening new avenues for combination regimens, and gene therapy vectors (AAV-DRD1) are being explored for refractory PD subtypes. As the field moves beyond orthosteric ligands, allosteric modulation and peptide/peptidomimetic approaches are gaining traction for addiction disorders and cognitive impairment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonists (including biased) | Cerevel (AbbVie), Pfizer, CNS-focused biotechs | Parkinson's Disease, Cognitive Deficits | Subtype selectivity & cAMP bias profiling (Need stable DRD1 lentivirus cell lines). |
| Positive Allosteric Modulators (PAMs) | Eli Lilly, Neurocrine, Domain Therapeutics, Confo | Schizophrenia (negative symptoms), Cognition | Conformation-specific binding (Requires native expression via ORF/Lentivirus). |
| Gene Therapy (AAV-DRD1) | AskBio, Bayer, Preclinical Academic Labs | Refractory Parkinson's, DRD1-deficient subtypes | Transduction efficiency & expression (Need precise ORF & reliable antibody controls). |
| Peptide/Peptidomimetics | PeptiDream, Bicycle | Addiction Disorders | Internalization kinetics (Flow cytometry with stable cell lines). |
| Biased Ligand / Trafficking Modulator | Translational neurobiology programs | Addiction, Neurodegeneration | β-arrestin recruitment vs Gs bias (Need flow-validated DRD1 stable cells). |